NovoSorb® Biodegradable Temporising Matrix (BTM): What we learned from the first 300 consecutive cases

• Published in: Journal of plastic, reconstructive & aesthetic surgery reconstructive & aesthetic surgery, 2024-05, Vol.92, p.190-197
• Main Authors: Tapking, Christian, Thomas, Benjamin Felix, Hundeshagen, Gabriel, Haug, Valentin Felix Michel, Gazyakan, Emre, Bliesener, Björn, Bigdeli, Amir Khosrow, Kneser, Ulrich, Vollbach, Felix Hubertus
• Format: Article
• Language: English
• Subjects: Absorbable Implants; Adult; Aged; Biodegradable Temporising Matrix; BTM; Burns; Dermis substitute; Female; Humans; Male; Middle Aged; Plastic Surgery Procedures - adverse effects; Plastic Surgery Procedures - methods; Retrospective Studies; Risk Factors; Skin Transplantation - adverse effects; Skin Transplantation - methods; Skin, Artificial; Soft Tissue Injuries - etiology; Soft Tissue Injuries - surgery; Take rate
• ISSN: 1748-6815; 1878-0539
• DOI: 10.1016/j.bjps.2024.02.065

Extensive full-thickness soft-tissue defects remain a challenge in reconstructive surgery. NovoSorb® Biodegradable Temporising Matrix (BTM) represents a novel dermal substitute and was evaluated in wounds deriving from different aetiologies and to highlight risk factors for poor take rates. All patients treated with BTM at our department between March 2020 and October 2022 were included. Differences in univariate and linear regression models identified predictors and risk factors for take rates of BTM and split-thickness skin grafts (STSG). Three hundred patients (mean age 54.2 ± 20.1 years, 66.3% male, 59.7% burns, 19.7% trauma and 20.6% others) were evaluated. Mean take rates of BTM and STSG after BTM delamination were 82.7 ± 25.2% and 86.0 ± 22.6%, respectively. Multiple regression analyses showed that higher body mass index (BMI, OR 0.43, 95% CI 0.86, −0.01, p = 0.44), prior allograft transplantation (OR 15.12, 95% CI 26.98, −3.31, p = 0.041), longer trauma-to-BTM-application intervals (OR 0.01, 95% CI 0.001, −0.001, p = 0.038), positive wound swabs before BTM (OR 7.15, 95% CI 13.50, −0.80, p = 0.028) and peripheral artery disease (OR 10.80, 95% CI 18.63, −2.96, p = 0.007) were associated with poorer BTM take. Higher BMI (OR 0.40, 95% CI 0.76, −0.08, p = 0.026), increasing BTM graft surface areas (OR 0.58, 95% CI −1.00, −0.17, p = 0.005), prior allograft (OR 12.20, 95% CI −21.99, −2.41, p = 0.015) or autograft transplantations (OR 22.42, 95% CI 38.69, −6.14, p = 0.001), tumour as the aetiology of the wound (OR 37.42, 95% CI 57.41, −17.83, p = 0.001), diabetes (OR 6.64, 95% CI 12.80, −0.48, p = 0.035) and impaired kidney function (OR 5.90, 95% CI 10.94, −0.86, p = 0.021) were associated with poorer STSG take after delamination of BTM, whereas higher BTM take rates were associated with better STSG take (OR 0.40, 95% CI 0.31,0.50, p